Research

More than 50 research studies to understand, detect, treat and prevent the coronavirus in children and families have launched at Seattle Children’s since the virus emerged in late 2019. This is the first post in a new weekly series called “Quest(ion) for Discovery” highlighting this research in progress and the search for answers that could result in major scientific breakthroughs that save lives and slow the spread of the virus.

As the senior vice president and chief academic officer at Seattle Children’s, Dr. Leslie R. Walker-Harding helps set the vision for Seattle Children’s Research Institute, one of the top five pediatric research programs in the country. Here she addresses the question: Can a greater understanding of COVID-19 in children reduce the overall impact of the coronavirus?

Read full post »

Although children don’t typically fall seriously ill from the new coronavirus, doctors in Europe are now expressing concern that children with COVID-19 have developed mysterious symptoms that mimic those appearing with Kawasaki disease.

On the Pulse asked Dr. Michael Portman, pediatric cardiologist and director of the Kawasaki Disease Clinic at Seattle Children’s, to help break this emerging issue down for parents and caregivers. Read full post »

Eighteen months ago, Dr. Lynn Martin, an anesthesiologist and medical director of the ambulatory surgery center at Seattle Children’s, and his colleagues at the Seattle Children’s Bellevue Clinic and Surgery Center set out to reduce the use of opioids during outpatient pediatric surgeries, while maintaining or improving pain management and outcomes for patients. Ultimately, they accomplished much more by successfully ousting opioid use during surgeries.

According to the Centers for Disease Control and Prevention (CDC), drug overdose deaths continue to increase in the U.S. It is a problem Martin and his colleagues believe they can help address, which is what drove them to develop a novel initiative at Seattle Children’s to reduce opioids.

Martin and his colleagues completed their breakthrough quality improvement initiative to reduce opioid use and their findings were published in Anesthesia and Analgesia. Read full post »

A curb side initial screening for COVID-19 symptoms allows nurses to determine if a patient needs isolation before entering the Emergency Department. (Slide 1/6)

If a patient is showing potential symptoms of COVID-19 and needs to be cared for in the hospital, then they are admitted to Seattle Children’s Special Isolation Unit (SIU). This photo was taken during a recent simulation training in the SIU. (Slide 2/6)

Dr. Whitney Harrington, a pediatric infectious disease specialist, plans to launch a study that will provide valuable epidemiological data from a community cohort on who’s becoming infected, when they’re becoming infected, and who’s getting sick from the infection. (Slide 3/6)

The Coler Lab at Seattle Children’s Research Institute is using their expertise to support the clinical trial of an experimental coronavirus vaccine. (Slide 4/6)

Another collaborative research effort led by Dr. Peter Myler, a principal investigator at Seattle Children’s, has already contributed findings about for vaccine development efforts and new knowledge generated daily is expected to aid in drug development. (Slide 5/6)

Children and teens trying to make sense of what the COVID-19 pandemic means for their families and communities may feel more worry than usual. Any caregiver can take steps to help children and teens cope during this stressful time. (Slide 6/6)

When health officials learned a Seattle Children’s patient tested positive for the novel coronavirus 2019 (COVID-19) in late February, it sent a ripple through health and scientific communities nationwide. It was the first example of community transmission in the state of Washington, indicating the virus causing COVID-19 had likely been spreading in Seattle and the surrounding region undetected.

It was a moment Seattle Children’s had prepared to face since establishing an incident command center more than one month prior. From this command center, teams from across the organization met to support advance planning and coordinate actions for a potential COVID-19 surge in the region.

“Before there were any confirmed cases in the U.S., Seattle Children’s anticipated the potential for an outbreak in our region,” said Dr. Jeff Sperring, Seattle Children’s Chief Executive Officer. “Over the past several weeks, we have provided specialized training for our team, established strict protocols for health and hygiene, and consolidated essential supplies so that we would be ready to protect our patients.”

Now other cities are turning to Seattle for insight on what to expect as the growing pandemic reaches their communities. On the Pulse offers a behind the scenes look at how the leading pediatric hospital and research institute at the epicenter of the country’s COVID-19 outbreak is responding to this quickly evolving global health issue. Read full post »

Worry flooded Candice Andrews’ mind as doctors wheeled her newborn son away for open heart surgery.

“I knew about his heart condition since I was 7 months pregnant,” Andrews said. “However, it was still very scary knowing that someone was going to do surgery on my 7-day old baby.”

Andrews’ son, Marcus, was born with hypoplastic left heart syndrome, a rare and serious birth defect that occurs when the left side of the heart is not fully developed.

Fortunately, Marcus recovered well after his first of what would be three surgeries needed to treat his heart condition.

“Doctors mentioned how exceptional his recoveries were,” Andrews said. “We were so grateful, given how unknown the entire situation was for us.”

Although his first few years of a life were a bit rocky, Marcus remained relatively healthy as he progressed through childhood.

Read full post »

Dr. Bonnie Ramsey (left) and Dr. Ann Dahlberg (right), are not only mother-daughter but also fellow clinical researchers and at Seattle Children’s.

When Dr. Bonnie Ramsey entered medical school at the advice of an undergraduate professor in the early 1970s, she and her female classmates at Harvard Medical School were still among the early coteries of women to pursue careers in science and medicine.

“We were the first bolus of women,” Ramsey said, using the medical term to describe their injection into a field dominated by male physicians. “It was interesting. When you are the first cohort, there is a tendency to compete with each other rather than work as a team.”

Since finding her footing in those early days, Ramsey has pioneered therapies improving the lives of children with cystic fibrosis (CF). Today, she leads all clinical research efforts at Seattle Children’s as the director of the Center for Clinical and Translational Research.

Her career will no doubt leave a lasting impact for the future physicians, researchers and women that will follow her, but for Ramsey, it’s a personal legacy that makes her most proud. Over the last decade, she’s watched her daughter enter the medical field and become a formidable physician-scientist in her own right.

“I am so incredibly proud of her,” Ramsey said. “Watching what she has to juggle and balance is in some ways harder for me than doing what I did with no real generation ahead of me to look to for guidance.” Read full post »

Digital devices like the iPad have only been around for about 10 years, but in that short amount of time, they have become ingrained into everyday life and research examining their impact on young children is limited.

Dr. Dimitri Christakis, director of the Center for Child Health, Behavior and Development at Seattle Children’s Research Institute, was featured on the TODAY Show to discuss the evolving digital age children are growing up in. Watch as three families learn more about how their children interact with devices like the iPad and hear about the challenges Christakis faces as technology continues to advance at a much faster rate than our understanding of the impact of digital devices on a child’s developing mind.

It may seem as though digital devices and touch screens like the iPad have been around for decades, but the reality is that these devices have only been around for about 10 years. In that short amount of time, they have become ingrained into everyday life, but research on their impact is limited. What concerns researchers like Dr. Dimitri Christakis is that we don’t yet understand the effects these devices may have on young children, and so that’s why they’ve taken center stage in many of his research studies.

Christakis isn’t advocating for taking screens away from children. He simply hopes he can help parents and caregivers better understand and navigate how devices like the iPad can fit into their lives in a healthy way.

“The point isn’t that we should take away all digital devices, but rather that we should come at it from a different perspective,” Christakis said. “We should ask, ‘How can we help children live healthy lives in a digital world that they’re immersed in from birth?” Read full post »

Taylor Tran (left) and her mother Mai Nguyen. Taylor underwent cancer treatment when she was 2 years old, causing her to go into early menopause when she was just 16.

“You pay the price for having cancer over and over again.”

Mai Nguyen’s words are loaded with sorrow as she speaks about her 17-year-old daughter, Taylor Tran, who is dealing with fertility concerns more than a decade after she survived late-stage cancer.

It’s easy to understand the exasperation Nguyen feels: Her daughter was diagnosed with stage 3 single-cell sarcoma of the kidney when she was 2 years old and was treated with intense chemotherapy and radiation. Now, the treatments that saved her life have put her into early menopause.

“It’s been traumatic,” Nguyen said. “We’ve tried so hard to allow Taylor to have a normal childhood and this feels like one more thing cancer has taken from her.”

Stories like Taylor’s inspired Seattle Children’s urologist Dr. Margarett Shnorhavorian to tackle a challenging area of research that was largely uncharted more than a decade ago. Since then, she’s helped change perspectives and protocols for fertility preservation in childhood cancer survivors. Read full post »

Ellie Osterloh, 17, participated in the clinical trial for Trikafta, a breakthrough cystic fibrosis therapy approved by the U.S. Food and Drug Administration in October 2019. Photo courtesy of Audrey Redfern.

When 17-year-old Ellie Osterloh spins high above the ground from a lyra, a circular hoop used in aerial acrobatics like Cirque du Soleil, she feels empowered.

“On the lyra, it’s an incredible feeling to be so high in the air with no harnessing,” Ellie said. “It’s a lot of adrenaline and I feel like I can do anything.”

Now, thanks to Trikafta, a new drug approved in October 2019 by the U.S. Food and Drug Administration (FDA), Ellie, who participated in the clinical trial for the drug, shares a similar zeal for her future.

“Even though it’s hard sometimes to be so optimistic, I’ve always thought it might be possible to go to college and have kids and a family of my own,” she said. “It’s crazy how my outlook has changed. I’m still processing all the possibilities.”

That’s because Ellie has lived her entire life with cystic fibrosis, a rare, progressive, life-threatening disease. She had her first appointment with Dr. Bonnie Ramsey, the director of Seattle Children’s Center for Clinical and Translation Research, still in her mother’s womb. Hours after birth she was transferred to Seattle Children’s where she began intensive therapy that she’s continued over the last 16 years.

“This is a really big step forward for Ellie and other people living with cystic fibrosis,” said Ramsey, a pioneer in cystic fibrosis treatment. “Ellie is a highly talented young lady with a bright future ahead of her.” Read full post »

Madeline Boese was one of the patients in Seattle Children’s PLAT-03 trial.

Chimeric antigen receptor (CAR) T-cell immunotherapy, which reprograms a child’s white blood cells so they can seek out and destroy cancer cells, is making a difference in children’s lives. Currently, Seattle Children’s has multiple trials open that could benefit children and young adults with relapsed or refractory cancers. In October, Seattle Children’s opened a new pediatric research facility, Building Cure, to accelerate discoveries such as immunotherapy.

Seattle Children’s researchers are continuing to realize the promise of CAR T-cell immunotherapy and improve outcomes in difficult to treat pediatric cancers. They are applying knowledge gained from ongoing clinical trials to study effects on the youngest patients, develop new interventions to prevent side effects and boost T-cell persistence, and to better understand resistance to therapy.

Research recently published in major scientific journals and presented at the 2019 American Society of Hematology (ASH) Annual Meeting contributes new insight guiding the evolution of the experimental therapy. Here, On the Pulse summarizes their findings. Read full post »